Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

7Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as “first-in-class” (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong. The 2023 novel drug list also demonstrates an unabated emphasis on polypeptides (recombinant proteins and antibodies), Advanced Therapy Medicinal Products (gene and cell therapies) and RNA therapeutics, including the first-ever approval of a CRISPR-Cas9-based gene-editing cell therapy.

Cite

CITATION STYLE

APA

Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M., Kendall, D. A., Martemyanov, K. A., … Ferdinandy, P. (2024, June 1). Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. British Journal of Pharmacology. John Wiley and Sons Inc. https://doi.org/10.1111/bph.16337

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free